News about PKU: research, treatments, education and community, each linked to its original source.
August 24, 2026 · Treatments
PTC announced new data for the SSIEM 2026 congress on phenylalanine reduction and greater dietary flexibility with sepiapterin. The results reported by the manufacturer include trials and clinical practice experience. Response must be evaluated individually and any change in diet requires supervision from the treating team.
Read the PTC release →August 6, 2026 · Community and innovation
NPKUA reported that its conference, held July 16-19 in Illinois, brought together more than 600 people from nine countries. During the event, USD 150,000 was raised to support the development and approval of at-home phenylalanine meters. This is progress in funding, not the announcement of a device ready for use.
Learn about NPKUA's initiative →August 2, 2026 · Education
E.S.PKU announced a collection of eleven infographics based on the revised European guidelines. The materials explain topics such as diet, phenylalanine monitoring, treatments, neuropsychological assessment and transition to adult care. They are aimed at professionals, organizations, patients and families.
See E.S.PKU's resources →June 28, 2026 · Emotional well-being
On the occasion of International PKU Day, E.S.PKU put the focus on the mental health of patients, families and organization representatives. The campaign gathers experiences about the emotional toll of supporting other people and highlights the need to also support those who dedicate their time to advocating for the community.
Read E.S.PKU's post →June 18, 2026 · Research
Beam Therapeutics announced that the FDA authorized moving forward with clinical research on BEAM-304, an experimental therapy designed to correct certain variants of the PAH gene. The program contemplates a phase 1/2 trial to evaluate safety and effects on phenylalanine. This authorization allows research to proceed: it does not amount to approving a treatment or demonstrating a cure.
Read Beam's announcement →February 27, 2026 · Approvals
The FDA expanded the indication of pegvaliase to patients age 12 and older with PKU and phenylalanine above 600 µmol/L despite existing management. The decision was based on the PEGASUS study. The treatment requires specific safety measures due to the risk of serious allergic reactions, including anaphylaxis.
Read the BioMarin release →